Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Predicting global diet-disease relationships at the atomic level: a COVID-19 case study  
Lennie KY Cheung and Rickey Y Yada

Over the past few months, numerous studies harnessed in silico methods such as molecular docking to evaluate food compounds for inhibitory activity against coronavirus infection and replication. These studies capitalize on the efficiency of computational methods to quickly guide subsequent research and examine diet-disease relationships, and their sudden widespread utility may signal new opportunities for future antiviral and bioactive food research. Using Coronavirus Disease 2019 (COVID-19) research as a case study, we herein provide an overview of findings from studies using molecular docking to study food compounds as potential inhibitors of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), explore considerations for the critical interpretation of study findings, and discuss how these studies help shape larger conversations of diet and disease.

Address  
Faculty of Land and Food Systems, University of British Columbia, Vancouver, BC V6T 1Z4, Canada

Corresponding author: Yada, Rickey Y (R.Yada@ubc.ca)

Accelerated food research in the pandemic world
The Coronavirus Disease 2019 (COVID-19) pandemic has led to a rapid increase of research on antiviral food-derived compounds, specifically those targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Food compounds with biological activities in addition to their nutritional properties are generally considered safer for consumption than synthetic pharmaceutical drugs and have been receiving renewed interest in recent years as templates for drug design in light of genomic and technological advances [1]. Emerging evidence for the apparent protective effects of certain dietary practices and nutritional status on COVID-19 susceptibility and recovery further highlight the potential biological importance of antiviral and other bioactive food compounds [2–4]. Indeed, food-derived polyphenols have demonstrated antagonistic properties against SARS-CoV, which was the culprit behind the 2003 SARS outbreak, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and other viruses [5–7].

While in vitro approaches have been and continue to be widely used to assess antiviral activity, the urgency and severity of the pandemic has prompted many studies to adopt in silico methods, which can predict molecular interactions much faster than in vitro approaches and with atomic-level detail. In particular, molecular docking has been used in numerous studies, oftentimes as a sole method, to screen food compounds for SARS-CoV-2 inhibitory activity. Although this method has been increasingly used in contemporary food science, it is predominantly used to evaluate molecular interactions during nutrient metabolism, and between bioactive peptides or functional, taste-inducing, or harmful compounds and their respective targets [8–10]. The vast majority of these studies employ molecular docking after in vitro, or even in silico [11], testing to assess the mechanisms underpinning observed results. Against a new target and its alarming threat on global health, however, the sole application of computational methods allowed for screening studies to be rapidly conducted and communicated. These studies capitalize on not only the efficiency of computational methods, but also the expanding databases of food-sourced compounds, decades of research on antiviral food compounds, and timely discoveries of SARS-CoV-2 from other fields including structural biology and pharmaceutical science. This recent surge of research thus presents a unique opportunity to assess COVID-19 as a case study for how molecular docking can be used in food research to understand diet-disease relationships.

Molecular docking for drug discovery
Molecular docking is a computational technique commonly used in pharmaceutical science to predict the fit of a compound to a target substrate, which is oftentimes a protein of clinical or functional importance. The determination of fit varies depending on the algorithms used and may take into account molecular spatial orientation, statistical models, and physicochemical interactions [12]. Using the structural information of both target and ligands, sampling algorithms first generate multiple conformations of each ligand associating with the target and scoring functions subsequently assign numeric scores to...
each conformation and rank the overall scores [13]. The highest scored ligands are most likely to form stable complexes with the target, and therefore have highest potential to disrupt the function and activity of the protein target. Atomic-level interactions between each ligand-substrate pair can also be inferred from the docking results.

The efficiency and growing accuracy of molecular docking at evaluating large catalogs of compounds — exceeding 1 million in some cases [14] — for specific targets has increased the use of this technique in computer-aided pharmaceutical drug design workflows over the past few decades. Studies utilizing this method have played critical roles in the development of currently available drugs for the treatment of Human Immunodeficiency Virus (HIV) and influenza, and have contributed in the search for potential treatments of cancer, malaria, and other diseases [15]. Beyond screening and optimizing ligand potency for subsequent validation, this method has increasing applications in other aspects of drug design including side effect prediction or multi-target evaluation related to a single disease [16]. Molecular docking was thus rapidly implemented into the search for potential COVID-19 treatment strategies once the structures of notable SARS-CoV-2 proteins were solved [17,18].

### Potential SARS-CoV-2 inhibitors from foods

Over the last few months, numerous studies have used molecular docking to screen food compound libraries for candidate inhibitors of SARS-CoV-2, albeit with different approaches. Several studies screened large databases of ca. 10 000 to over 162 000 food constituents for candidate compounds [19,20,21*,22*]. Casting a wide net allowed these researchers to identify specific chemical features that may be integral for strong association with the target substrate. For example, compounds that contained aromatic nitrogen atoms [20] and polycyclic structures were predicted to form strong associations with residues within the active site of SARS-CoV-2 main protease (MPro), a crucial protein of coronavirus replication [22*]. Other researchers took a more targeted approach in their screening and focused on specific compound types when curating libraries of potential ligands. A common strategy was to screen compounds previously associated with antiviral activity, such as polyphenols. From these studies, polyphenols from green tea [23], pomegranate peel [24], honey and propolis [25]; flavonoids from citrus [26] and other sources [27,28]; and tannins [29] were reported to have high predicted potency against SARS-CoV-2 MPro.

Rather than focus on specific compound types, some researchers opted to conduct food-oriented exploratory expeditions. Such studies evaluated known compounds of specific foods such as spices [30,31], cinnamon [32], olives [33*], and teas [34]. Interestingly, a large number of studies evaluated foods that are traditionally associated with medicinal properties and ethnopharmacological usage. Authors of such studies screened libraries of compounds curated based on literature review or traditional knowledge [35–40], their presence in medicinal ingredients such as black cumin (Nigella sativa) [41,42], or chemical identification by chromatographic and spectrometric analyses of medicinal foods such as garlic oil, horchata, and Liupao tea [43,44*,45]. The drug-likeness of highly ranked compounds was determined in many of these studies using in silico assessments of their pharmacokinetic and toxicological properties, with authors concluding that high-ranking compounds have potential for lead optimization into drug candidates and warrant further experimental validation, although such validation studies currently remain scarce. The identification of potential antiviral compounds from these studies were typically presented as supporting evidence for the purported antiviral activities of the food sources.

Food compounds that exhibit non-antiviral biological or functional properties were also curated and assessed for potential activity against SARS-CoV-2. Wahedi et al. [46] evaluated stilbenes, which are associated with anti-tumor, anti-inflammatory, and other biological activities, with the aim of repurposing them as agents against COVID-19 and found that resveratrol may have potent activity inhibiting the host-virus interactions mediated by SARS-CoV-2 spike protein. Food-derived peptides with purported anti-hypertensive activity were predicted to interact with various targets of SARS-CoV-2 and demonstrated potential as lead compounds for COVID-19 treatment [47]. Nisin, a well-established and common food preservative with known antimicrobial activity, was reported for the first time to potentially possess antiviral activity via interactions with human angiotensin-converting enzyme 2 (ACE2), a protein involved in coronavirus-host recognition [48]. These studies mirror pharmaceutical drug repurposing research, which seek to identify new therapeutic uses for drugs that are already extensively studied, approved, or discontinued. By taking advantage of the research and development already conducted on existing compounds, drug repurposing expedites the search for new drugs. Considering the examples listed above, it is possible, then, that repurposing studies on food ingredients and approved additives may also help expedite the search for new bioactive food ingredients.

### Proteins may release antiviral peptides after digestion

In contrast to treating food as a cornucopia of potentially therapeutic compounds as described above, some researchers have sought to screen for compounds that may be released by digestive enzymes after consumption. Studies using this approach assessed bioactive peptides...
released from dietary proteins from grains, seeds [49,50], and microalgae [51]; fish [52] and squid [53]; and soy cheese [54]. While some studies followed the modern omics approach, wherein peptides are first isolated and identified in vitro using liquid chromatography and mass spectrometry [49,54*], most of these studies adopted an entirely in silico approach that used simulated gastrointestinal digestion to predict the resulting mixture of hydrolyzed peptides. Also unlike contemporary bioactive peptide research, which typically focus on peptides as a purified end product [9], several studies listed here also considered the applicability of the source protein as nutritional interventions for COVID-19 patients [50–53]. Aside from peptides, intact proteins from bee-secreted royal jelly with antiviral activity against Hepatitis C and B viruses [55] were also predicted to associate with several SARS-CoV-2 and host targets [56], although the mode of delivery of these proteins for COVID-19 remains to be explored.

**Links between diet and COVID-19 susceptibility**

The use of molecular docking in food and nutritional sciences to explain or theorize relationships between diet and disease susceptibility has emerged during the pandemic. When epidemiological analysis revealed that countries with marine-sourced dietary omega-3 fatty acids had lower fatality rates of COVID-19, Vivar-Sierra et al. [57] used molecular docking results to help propose that a possible explanation was impeded host entry due to omega-3 fatty acids reinforcing the closed (i.e. inaccessibility) conformation of the SARS-CoV-2 spike protein. Chowdhury et al. [58] used molecular docking to suggest that the strong association predicted between choline and SARS-CoV-2 M<sub>pro</sub> could help explain earlier observations that higher choline levels in expecting mothers who were infected with COVID-19 may have protective effects for fetal brain development. As a final example, Wang et al. [22*] postulated that the higher consumption rates of beer and tea, both of which they reported as sources of potentially potent SARS-CoV-2 M<sub>pro</sub> inhibitors after screening 10,870 food compounds, may play a role in the fast recovery of Germany and China, respectively, after their initial waves of COVID-19.

**Critical interpretation of results**

Although the recent increase in docking research led to some compounds being evaluated in multiple studies, direct comparative analyses of results among studies are rare [52,59] and challenging due to differing methodologies [60]. For example, although Rout et al. [31] and Ibrahim et al. [37] both evaluated the ginger compounds gingerol, shogaol, and zingerone against M<sub>pro</sub>, their use of different docking software and starting protein structures may contribute to their discrepancies in ranking; while the former study scored these compounds closely (−5.8 to −6.1 kcal/mol), gingerol and shogaol were scored higher (−7.1 and −7.4 kcal/mol, respectively) than zingerone (−5.7 kcal/mol) in the latter study. Further, while both studies scored the former two compounds lower than capsaicin and piperine, the analysis by Umesh et al. [30] scored them both higher.

When interpreting recent study findings, another aspect to consider is how the molecular docking results were processed. While many studies discussed in this review aimed to identify lead compounds for optimization into potent drugs using molecular docking as a primary method, computer-aided drug design often implements molecular docking into longer workflows with pre-docking and post-docking data processing using molecular dynamics, artificial intelligence, statistical methods, and other methods to improve the accuracy of obtained results [16]. Molecular docking itself also undergoes constant improvement in pharmaceutical science, exemplified by recent advances in dataset benchmarking and the use of consensus scoring or machine learning for more accurate results [61]. Although some of the studies in this overview included molecular dynamics as a post-docking assessment, many lack additional data processing steps. The short production times of molecular dynamic simulations used in some studies also lack missing important changes in binding stability [43,47,58], changes of which occur over timescales of 100–200 ns [19,22*]. Specific workflows may also be required depending on the analytes evaluated. For example, a rigorous filtering protocol with positive and negative controls can mitigate false positives when screening flavonoids [60].

Beyond experimental set up, the results obtained from molecular docking studies must also be contextualized by the narrow scope of the analysis. For example, while molecular docking can predict direct interactions between food constituents and disease targets with high precision, actual nutritional modulation of the body’s response to disease may extend beyond such associations and involve complex cell signaling pathways that cannot be inferred from docking results alone. The protein structures used may also lack physiological context, such as the glycan shielding and crowding effects on SARS-CoV-2 spike protein [62]. Furthermore, the typically low bioavailability of high-ranking compounds has cast doubt on the applicability of recent study findings [63], although some researchers have proposed that active compounds be incorporated into nanoparticles or pharma-nutraceutical formulations to improve uptake [35,64*] or administered as throat rinses [53]. Docking studies alone also provide minimal insight on the dosage required of a compound to elict physiological or temporal effects.

Despite the limited scope of standalone studies, the recent increase in docking studies facilitate the observation of general trends. For example, many highly ranked
compounds with predicted inhibitory activity against M^{pro} contain polycyclic structures [22*,31,33*] or, in the case of peptides, amino acid residues containing ring structures [50,53]. Compounds such as epicatechin and its derivatives [23,27,44*] and hesperidin were also consistently ranked highly as candidate inhibitors of various targets involved in SARS-CoV-2 infection and replication [36,40,64*,65*]. Reviewing the results from multiple studies can provide additional context for the findings from standalone studies. Fatty acids, for example, may still offer protective roles against COVID-19 despite low predicted association with SARS-CoV-2 M^{pro} [22*] by complexing with other viral targets [57*]. Similarly, although organosulfur compounds such as diallyl disulfide and diallyl trisulfide from garlic scored relatively low among spice compounds for M^{pro} [30,37], further investigation into these compounds may still be warranted due to their abundance in garlic oil — together accounting for over 51% of constituents — and predicted interaction with ACE2 [45].

Translatability of findings
While examples of translatability between molecular docking results and clinical effect exist in drug discovery [15], such translations for food components and disease are less abundant. Epicatechin and its derivatives [27,44*] and high-ranking flavonoids [28] were reported to exhibit potent in vitro inhibitory activity against M^{pro}. The antiviral activity of hesperidin against SARS-CoV-2 [65*] and hepatitis A virus as a model RNA virus has also been demonstrated in cellular and plaque assays, respectively [64*]. Considering these limited examples and past research on the antiviral activities of polyphenols [5], the results reported from recent docking studies may be translatable to in vitro experimental results at least for some plant compounds. However, the in vitro inhibitory activity of food components against SARS-CoV-2 remains largely unknown since suitable animal models for COVID-19 remain under active development [66,67]. It is thus difficult to fully assess the applicability of recent findings on the treatment of or protection against COVID-19 at this time.

Even considering the lack of research evaluating the nutritional and clinical contributions of recent molecular docking studies on food components, the increased use of molecular docking in food research has demonstrated the practicality of this method for enriching discussions of food and its effects on disease susceptibility. Using COVID-19 research as a case study, it becomes evident that molecular docking allowed researchers to respond very quickly to an urgent global health issue and contribute to conversations of diet-disease relationships by conducting large-scale screening of food antivirals for drug development, exploring nutritional intervention strategies, and searching for the molecular basis behind epidemiological trends. Such conversations will become even more important as the search for treatments against SARS-CoV-2 continues and the world seeks to prepare for post-pandemic normality. Already, evidence linking plant-rich diets with protective effects against COVID-19 is mounting [3,4]. Deficiencies in certain vitamins and micronutrients have also been associated with increased COVID-19 hospitalization and mortality, and the applicability of these nutrients as interventional strategies may become clearer as more data is collected from ongoing clinical trials [2]. While further validation studies are still required to demonstrate clinical effects, the critically interpreted results from molecular docking studies can provide insights to guide subsequent research and a starting point for theorizing diet-disease relationships. These recent trends may thus provide impetus for future antiviral and bioactive food research to continue leveraging molecular docking when applicable. Whether the recent widespread utility of this method is an artefact of a severe pandemic, however, or signals new opportunities for bioactive food research remains to be seen.

Conflict of interest statement
Nothing declared.

Acknowledgement
This work was supported by the Natural Sciences and Engineering Research Council of Canada (Grant no. RGPIN 04598 and the CGS D program).

References and recommended reading
Papers of particular interest, published within the period of review, have been highlighted as:
* of special interest
1. Atanasov AG, Zotev SV, Dirsch VM, Orhan IE, Banach M, Rollinger JM, Barreca D, Weckwerth W, Bauer R, Bayer EA et al.: Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov 2021, 20:200-216.
2. Clemente-Suárez VJ, Ramos-Campo DJ, Mielgo-Ayuso J, Dalamitros AA, Nikolaidis PA, Hornero-Holgado A, Tomero-Aguliera JF: Nutrition in the actual COVID-19 pandemic. A narrative review. Nutrients 2021, 13:1924.
3. Kim H, Rebholz CM, Hegde S, Lafuente C, Raghavan M, Lloyd JF, Cheng S, Seidelmann SB: Plant-based diets, pescatarian diets and COVID-19 severity: a population-based case-control study in six countries. BMJ Nutr Prev Health 2021, 4:257-266.
4. Losso JN, Losso MN, Toc M, Inungu JN, Finley JW: The young age and plant-based diet hypothesis for low SARS-CoV-2 infection and COVID-19 pandemic in sub-Saharan Africa. Plant Foods Hum Nutr 2021, 76:270-280.
5. Paraiso IL, Revel JS, Stevens JF: Potential use of polyphenols in the battle against COVID-19. Curr Opin Food Sci 2020, 32:149-155.
6. Arunkumar J, Rajarajan S: Study on antiviral activities, drug-likeness and molecular docking of bioactive compounds of Punica granatum L. to Herpes simplex virus - 2 (HSV-2). Microb Pathog 2018, 118:301-309.
7. Park J, Kim JH, Kwon JM, Kwon H, Jeong HJ, Kim YM, Kim D, Lee WS, Ryu YB: Dieckol, a SARS-CoV 3CL(pro) inhibitor, isolated from the edible brown algae Ecklonia cava. Biorg Med Chem 2013, 21:3730-3737.
8. Tao X, Huang Y, Wang C, Chen F, Yang L, Ling L, Che Z, Chen X: Recent developments in molecular docking technology.
Predicting diet-disease relationships at the atomic level: a COVID-19 case study

Cheung and Yada

5

applied in food science: a review. Int J Food Sci Technol 2020, 55:33-45.
9. Xu M, Gao H, Ma J, Yang C, Ji D, Agyei D: CHAPTER 17. Advances in the use of bioinformatics to discover biofunctional food peptides. In Food Proteins and Peptides: Emerging Biofunctions, Food and Biomaterial Applications. Edited by Udenigwe CC. The Royal Society of Chemistry; 2021:426-459.

10. Fitzgerald RJ, Cermeño M, Khalesi M, Kleekayal T, Amigo-Benavent M: Application of in silico approaches for the generation of milk protein-derived bioactive peptides. J Funct Foods 2020, 64:103636.

11. Ji D, Xu M, Udenigwe CC, Agyei D: Physicochemical characterisation, molecular docking, and drug-likeness evaluation of hypotensive peptides encrypted in flaxseed proteome. Curr Res Food Sci 2020, 3:41-50.

12. Meng Xuan-Yu, Zhang Hong-Xing, Mezei Mihaly, Cui M: Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des 2011, 7:146-157.

13. Guedes IA, de Magalhães CS, Dardennes LE: Receptor-ligand molecular docking. Biophys Rev 2014, 6, 75-87.

14. Oluibji O, Olagunju M, Keutmann M, Loschwitz J, Strodel B: High throughput virtual screening to discover inhibitors of the main protease of the coronavirus SARS-CoV-2. Molecules 2020, 25:3193.

15. Phillips MA, Stewart MA, Woodling DL, Xie Z-R: Has molecular docking ever brought us a medicine? In Molecular Docking. Edited by Vlachakis DP. IntechOpen; 2018:141-178.

16. Pinzi L, Rastelli G: Molecular docking: shifting paradigms in drug discovery. Int J Mol Sci 2019, 20:4331.

17. Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Zhang B, Li X, Zhang L, Peng G et al.: Structure of MPRO from SARS-CoV-2 and discovery of its inhibitors. Nature 2020, 582:289-293.

18. Trezza A, Iovinelli D, Santucci A, Prisci F, Spiga C: An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors. Sci Rep 2020, 10:13866.

19. Masand VH, Sk MF, Kar P, Rastija V, Zaki MEA: Identification of food compounds as inhibitors of SARS-CoV-2 main protease using molecular docking and molecular dynamics simulations. Chemom Intell Lab Syst 2021, 217:104394.

20. Zaki MEA, Al-Hussain SA, Masand VH, Akasup S, Bajaj SO, El-Sayed NNE, Ghosh A, Lewaa II: Identification of anti-SARS-CoV-2 compounds from food using QSAR-based virtual screening, molecular docking, and molecular dynamics simulation analysis. Pharmaceuticals 2021, 14:357.

21. Santibáñez-Morán MG, López-López E, Prieto-Martínez FD, Sánchez-Cruz N, Medina-Franco JL: Consensus virtual screening of dark chemical matter and food chemicals uncover potential inhibitors of SARS-CoV-2 main protease. RSC Adv 2020, 10:25089-25099.

This study screened over 100 000 food compounds using two similarity searching workflows, with 888 entries proceeding to evaluation using two docking programs. The 105 viable compounds warranting further testing were then categorized into four groups based on various attributes such as commercial availability and pharmacokinetic and toxicological properties.

22. Wang J, Zhang X, Omarini AB, Li B: Virtual screening for functional foods against the main protease of SARS-CoV-2. J Food Biochem 2020, 44:e13481.

This study organized over 10 000 compounds into 12 categories to evaluate using molecular docking. The binding stability of quercetin was further evaluated using molecular dynamics. Based on the analysis results, the importance of ring-structures for inhibiting SARS-CoV-2 main protease was discussed and links between the diet and COVID-19 were hypothesized.

23. Ghosh R, Chakraborty A, Biswas A, Chowdhuri S: Evaluation of green tea polyphenols as novel corona virus (SARS-CoV-2) main protease (Mpro) inhibitors – an in silico docking and molecular dynamics simulation study. J Biomed Struct Dyn 2021, 39:4362-4374.

24. Rakshit M, Muduli S, Srivastava PP, Mishra S: Pomegranate peel polyphenols prophylaxis against SARS-CoV-2 main protease by in-silico docking and molecular dynamics study. J Biomed Struct Dyn 2021:1-15 http://dx.doi.org/10.1080/07391102.2021.1979427.

25. Hashem HE: In silico approach of some selected honey constituents as SARS-CoV-2 main protease (COVID-19) inhibitors. Eurasian J Med Oncol 2020, 4:196-200.

26. Gogoi N, Chowdhury P, Goswami AK, Das A, Chetia D, Gogoi B: Computational guided identification of a citrus flavonoid as potential inhibitor of SARS-CoV-2 main protease. Mol Divers 2021, 25:1745-1759.

27. Zhu Y, Xie DY: Docking characterization and in vitro inhibitory activity of flavan-3-ols and dimeric proanthocyanidins against the main protease activity of SARS-CoV-2. Front Plant Sci 2020, 11:601316.

28. Jo S, Kim S, Kim DY, Kim MS, Shin DH: Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro. J Enzyme Inhib Med Chem 2020, 35:1539-1544.

29. Khalifa I, Zhu W, Mohammed HHH, Dutta K, Li C: Tannins inhibit SARS-CoV-2 through binding with catalytic dyad residues of 3CLpro, an in silico approach with 19 structural different hydrolysable tannins. J Food Biochem 2020, 44:e13432.

30. Umesh, Kundu D, Selvaraj C, Singh SK, Dubey VK: Identification of new anti-nCoV drug chemical compounds from Indian spices exploiting SARS-CoV-2 main protease as target. J Biomol Struct Dyn 2021, 39:3428-3434.

31. Rout J, Swain BC, Tripathy U: In silico investigation of spice molecules as potent inhibitor of SARS-CoV-2. J Biomol Struct Dyn 2020:1-15 http://dx.doi.org/10.1080/07391102.2020.1819879.

32. Prasanth DSNBK, Murahari M, Chandramohan V, Panda SP, Amakuri LR, Guntupalli C: In silico identification of potential inhibitors from Cinnamom main protease and spike glycoprotein of SARS-CoV-2. J Biomol Struct Dyn 2021, 39:4618-4632.

33. Thangavel N, Al Bratty M, Al Hazmi HA, Najmi A, Ali Alaqi RO: Molecular docking and molecular dynamics aided virtual search of OliveNet™ directory for secoiridoids to combat SARS-CoV-2 infection and associated hyperinflammatory responses. Front Mol Biosci 2021, 7:627767.

This study conducted a comprehensive in silico screening of olive compounds using three structure-based virtual screening docking programs, molecular dynamics, and pharmacokinetic and toxicological assessment.

34. Sharma J, Kumar Bhardwaj V, Singh R, Rajendran V, Purohit R, Kumar S: An in-silico evaluation of different bioactive molecules of tea for their inhibition potency against non structural protein-15 of SARS-CoV-2. Food Chem 2021, 346:128933.

35. Natesh J, Mondal P, Kaur B, Abdul Salam AA, Kasilingam S, Meeran SM: Promising phytochemicals of traditional Himalayan medicinal plants against putative replication and transmission targets of SARS-CoV-2 by computational investigation. Comput Biol Med 2021, 133:104383.

36. Gupta S, Singh V, Varadwaj PK, Chakravarty N, Katta AVSKM, Lekkala SP, Thomas G, Narasimhan S, Reddy AR, Reddy Lachagan VB: Secondary metabolites from spice and herbs as potential multitarget inhibitors of SARS-CoV-2 proteins. J Biomol Struct Dyn 2020:1-20 http://dx.doi.org/10.1080/07391102.2020.1837679.

37. Ibrahim MAA, Abdelrahman AHM, Hussien TA, Badr EAA, Mohamed TA, El-Seedi HR, Pare PW, Effert T, Hegazy MEF: In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors. Comput Biol Med 2020, 126:104046.

38. Pandey P, Rane JS, Chatterjee A, Kumar A, Khan R, Prakash A, Ray S: Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: an in silico study for drug development. J Biomol Struct Dyn 2021, 39:6306-6316.
This study identified 1420 peptides from soy cheese using LC-MS/MS, all of which were pre-screened for antiviral activity using two predictive online servers. The resulting 23 peptides were evaluated for antiviral activity against two targets of SARS-CoV-2 using molecular docking, and the highest scored peptide further evaluated against targets of various SARS-CoV-2 proteases.

55. Habashy NH, Abu-Serie MM: Major royal-jelly protein 2 and its isoform X1 against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): insight on their sialidase activity and molecular docking. J Funct Foods 2020, 75:104985.

56. Vivar-Sierra A, Araiza-Macias MJ, Hernández-Contreras JP, et al.: Identification of potential plant bioactive as SARS-CoV-2 Spike protein and human ACE2 fusion inhibitors. Comput Biol Med 2021, 136:104631.

57. Jiménez-Avalos G, Vargas-Ruiz AP, Delgado-Pease NF, Olivos-Ramirez GE, Sheen P, Fernández-Báez M, Quillano M, Zimic M, Agurto-Arteaga A, Antiarrma R et al.: Comprehensive virtual screening of 4.8 k flavonoids reveals novel insights into allosteric inhibition of SARS-CoV-2 Mpro. Sci Rep 2021, 11:15452.

58. Dew P: Low bioavailability hinders drug discovery against COVID-19, guided by in silico docking. Br J Pharmacol 2021, 178:741-742.

59. Attia GH, Moemen YS, Youns M, Ibrahim AM, Abdou R, El Rayes MA: Antiviral zinc oxide nanoparticles mediated by hesperidin and in silico comparison study between antiviral phenolics as anti-SARS-CoV-2. Colloids Surf B Biointerfaces 2021, 203:111724.

60. Cheng FJ, Huyhn TK, Yang CS, Hu DW, Shen YC, Tu CY, Wu YC, Tang CH, Huang WC, Chen Y et al.: Hesperidin is a potential inhibitor against SARS-CoV-2 infection. Nutrients 2021, 13:2800.

This study used molecular docking to predict the potential of hesperidin and hesperidin to bind to two proteins involved in SARS-CoV-2 cellular entry. The inhibitory activity against various targets and antiviral activity of these compounds were subsequently studied using chemical and cellular assays, respectively.
66. Rosa RB, Dantas WM, De Nascimento JCF, da Silva MV, de Oliveira RN, Pena LJ: In vitro and in vivo models for studying SARS-CoV-2, the etiological agent responsible for COVID-19 pandemic. *Viruses* 2021, 13:379.

67. Hewitt JA, Lutz C, Florence WC, Pitt MLM, Rao S, Rappaport J, Haigwood NL: ACTIVating resources for the COVID-19 pandemic: in vivo models for vaccines and therapeutics. *Cell Host Microbe* 2020, 28:646-659.